Percutaneous microwave ablation of stage I medically inoperable non‐small cell lung cancer: Clinical evaluation of 47 cases. Issue 6 (25th June 2014)

• Record Type: Journal Article
• Authors: Yang, Xia; Ye, Xin; Zheng, Aimin; Huang, Guanghui; Ni, Xiang; Wang, Jiao; Han, Xiaoying; Li, Wenhong; Wei, Zhigang
• Is Part Of: Journal of surgical oncology. Volume 110:Issue 6(2014:Nov. 01)
• Page Start: 758
• Page End: 763
• Publication Date: 2014-06-25
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23701
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso23701-sec-0001" sec-type="section"> <title>Purpose</title> <p>To retrospectively evaluate safety and effectiveness of CT‐guided percutaneous microwave ablation (MWA) in 47 patients with medically inoperable stage I peripheral non‐small cell lung cancer (NSCLC).</p> </sec> <sec id="jso23701-sec-0002" sec-type="section"> <title>Methods</title> <p>From February 2008 to October 2012, 47 patients with stage I medically inoperable NSCLC were treated in 47 MWA sessions. The clinical outcomes were evaluated. Complications after MWA were also summarized.</p> </sec> <sec id="jso23701-sec-0003" sec-type="section"> <title>Results</title> <p>At a median follow‐up period of 30 months, the median time to the first recurrence was 45.5 months. The local control rates at 1, 3, 5 years after MWA were 96%, 64%, and 48%, respectively. The median cancer‐specific and median overall survivals were 47.4 and 33.8 months. The overall survival rates at 1, 2, 3, and 5 years after MWA were 89%, 63%, 43%, and 16%, respectively. Tumors ≤3.5 cm were associated with better survival than were tumors >3.5 cm. The complications after MWA included pneumothorax (63.8%), hemoptysis (31.9%), pleural effusion (34%), pulmonary infection (14.9%), and bronchopleural fistula (2.1%).</p> </sec> <sec id="jso23701-sec-0004" sec-type="section"> <title>Conclusions</title> <p>MWA is safe and effective for the treatment of medically inoperable stage I peripheral NSCLC. <italic>J. Surg. Oncol. 2014 110:758–763</italic>. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>